Recro Pharma Inc (REPH) Major Shareholder Healthcare Master Fun Broadfin Sells 76,000 Shares

Recro Pharma Inc (NASDAQ:REPH) major shareholder Healthcare Master Fun Broadfin sold 76,000 shares of the stock in a transaction dated Thursday, December 21st. The stock was sold at an average price of $9.87, for a total value of $750,120.00. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Healthcare Master Fun Broadfin also recently made the following trade(s):

  • On Wednesday, December 13th, Healthcare Master Fun Broadfin sold 93,237 shares of Recro Pharma stock. The shares were sold at an average price of $9.86, for a total value of $919,316.82.
  • On Tuesday, December 5th, Healthcare Master Fun Broadfin sold 100,000 shares of Recro Pharma stock. The shares were sold at an average price of $10.00, for a total value of $1,000,000.00.
  • On Tuesday, November 28th, Healthcare Master Fun Broadfin sold 47,549 shares of Recro Pharma stock. The shares were sold at an average price of $9.64, for a total value of $458,372.36.
  • On Thursday, November 30th, Healthcare Master Fun Broadfin sold 222,616 shares of Recro Pharma stock. The shares were sold at an average price of $9.58, for a total value of $2,132,661.28.
  • On Tuesday, November 21st, Healthcare Master Fun Broadfin sold 102,440 shares of Recro Pharma stock. The shares were sold at an average price of $9.50, for a total value of $973,180.00.
  • On Friday, November 24th, Healthcare Master Fun Broadfin sold 172,208 shares of Recro Pharma stock. The shares were sold at an average price of $9.45, for a total value of $1,627,365.60.

Shares of Recro Pharma Inc (REPH) opened at $8.87 on Friday. Recro Pharma Inc has a 52-week low of $5.81 and a 52-week high of $10.59. The stock has a market capitalization of $166.79, a P/E ratio of -4.05 and a beta of -0.50. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.59 and a quick ratio of 1.35.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Janney Montgomery Scott LLC lifted its position in shares of Recro Pharma by 76.9% in the second quarter. Janney Montgomery Scott LLC now owns 22,085 shares of the specialty pharmaceutical company’s stock valued at $155,000 after buying an additional 9,600 shares during the last quarter. Teachers Advisors LLC acquired a new stake in shares of Recro Pharma in the second quarter valued at approximately $162,000. California State Teachers Retirement System acquired a new stake in shares of Recro Pharma in the second quarter valued at approximately $169,000. JPMorgan Chase & Co. lifted its position in shares of Recro Pharma by 183.4% in the third quarter. JPMorgan Chase & Co. now owns 21,784 shares of the specialty pharmaceutical company’s stock valued at $197,000 after buying an additional 14,098 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. acquired a new stake in shares of Recro Pharma in the second quarter valued at approximately $215,000. 61.55% of the stock is owned by institutional investors.

REPH has been the subject of a number of analyst reports. Zacks Investment Research downgraded Recro Pharma from a “hold” rating to a “sell” rating in a research note on Wednesday, October 11th. Piper Jaffray Companies restated a “buy” rating and issued a $11.00 price target on shares of Recro Pharma in a research note on Friday, October 27th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $11.65.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.thelincolnianonline.com/2018/01/14/healthcare-master-fun-broadfin-sells-76000-shares-of-recro-pharma-inc-reph-stock-2-updated-updated-updated.html.

About Recro Pharma

Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.

Insider Buying and Selling by Quarter for Recro Pharma (NASDAQ:REPH)

Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply